HC Wainwright Reiterates “$1.10” Price Target for Senseonics (NYSE:SENS)

Senseonics (NYSE:SENS) received a $1.10 price target from analysts at HC Wainwright in a research note issued on Monday, June 2nd, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 122.67% from the company’s current price. HC Wainwright also issued estimates for Senseonics’ Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at ($0.01) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS, FY2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.03) EPS, FY2028 earnings at ($0.01) EPS and FY2029 earnings at $0.01 EPS.

SENS has been the topic of a number of other research reports. Mizuho began coverage on shares of Senseonics in a research note on Thursday, April 10th. They issued an “outperform” rating and a $2.00 price target on the stock. Wall Street Zen upgraded shares of Senseonics to a “sell” rating in a report on Monday, May 12th.

Senseonics Trading Down 1.2%

SENS stock traded down $0.01 during midday trading on Monday, hitting $0.49. 1,524,675 shares of the company’s stock were exchanged, compared to its average volume of 6,991,117. Senseonics has a one year low of $0.25 and a one year high of $1.40. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a market cap of $323.18 million, a PE ratio of -3.80 and a beta of 0.96. The stock’s fifty day moving average price is $0.58 and its 200-day moving average price is $0.68.

Institutional Investors Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. Raymond James Financial Inc. acquired a new position in Senseonics during the 4th quarter worth approximately $26,000. IFP Advisors Inc boosted its holdings in Senseonics by 120.9% during the first quarter. IFP Advisors Inc now owns 47,500 shares of the company’s stock worth $31,000 after purchasing an additional 26,000 shares during the last quarter. CTC Alternative Strategies Ltd. acquired a new stake in Senseonics in the 1st quarter valued at $31,000. HighTower Advisors LLC acquired a new stake in Senseonics in the 4th quarter valued at $32,000. Finally, Two Sigma Investments LP acquired a new position in shares of Senseonics during the 4th quarter worth about $36,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.